Abstract: Method and kit for providing visual effects on fibres, for example human keratin fibres. In the method, fibres are provided coated with a composition. The composition comprises monomer(s) and optionally a cosmetically acceptable carrier. The monomer(s) are capable of forming a polymer after exposure to heat. The monomer(s) are selected from the group consisting of acrylates monomers, methacrylate monomers, acrylamide monomers, methacrylamide monomers, styrene monomers, vinyl pyrolidinone monomers, vinylpyrrolidone monomers, and mixtures thereof. The monomer(s) have a molecular weight in the range from 100 g/mol to 5000 g/mol. The monomer(s) have a functionality of between 1 and 100. The composition has a kinematic viscosity of from 0.5 cSt to 1500 cSt, measured at 23° C. In the method, a forming means is applied onto the fibres. The forming means orders the composition into a pattern and is a conductor. In the method, the temperature of the forming means is raised to a temperature of from 40° C. to 150° C.

Abstract: The invention relates to hair sprays comprising a pressurized container and an aerosol composition, located therein, which includes, based on its weight, 20 to 80% by weight of at least one propellant, 0.1 to 20% by weight of at least one fixing polymer, and 0.01 to 5% by weight of esters of the formula (I), in which R1 stands for —H or —CH3, R2 for a straight-chain or branched alkyl group having 7 to 15 carbon atoms, and n for an integer from the group comprising 1, 2, 3, 4, 5, 6, 7, 8; the hair sprays bring about an improved hair feel, improved lightness of the hairstyle, and improved hair texture, also with further improvement of the hold.

Abstract: Proposed is Mono Ornithine—Ketoglutarate (mOKG) as a medicament, in particular for use in the treatment of disorders of hair follicles.

Abstract: An oral care composition with reduced bitterness containing polyquaternium-2, polyquaternium-17, and/or polyquaternium-18.

Abstract: An agent for oxidatively dyeing keratin fibers includes in a cosmetic carrier, (A) as developer, 4,5-diamino-1-(2-hydroxyethyl)-1H-pyrazole and/or one of the physiologically acceptable salts thereof, (B) as developer, at least one pyrimidine derivative selected from 2,4,5,6-tetraaminopyrimidine, 4-hydroxy-2,5,6-triaminopyrimidine, 2-hydroxy-4,5,6-triaminopyrimidine and/or one of the physiologically acceptable salts thereof, (C) as coupler, at least one m-diaminobenzene derivative selected from 2-(2,4-diaminophenoxy)ethanol, 1-methoxy-2-amino-4-(2?-hydroxyethylamino)benzene, 2,6-bis(2?-hydroxyethylamino)-1-methylbenzene, and/or one of the physiologically acceptable salts thereof, and (D) as coupler, at least one m-aminophenol derivative selected from 3-aminophenol, 5-amino-2-methylphenol and/or one of the physiologically acceptable salts thereof.

Abstract: Agents for oxidatively dyeing of keratinic fibers include in a cosmetic carrier, (A) as a developer, 4,5-diamino-1-(2-hydroxyethyl)-1H-pyrazole and/or one of the physiologically acceptable salts thereof, (B) as a developer, p-aminophenol and/or one of the physiologically acceptable salts thereof, (C) as a coupler, 2,6-bis(2?-hydroxyethylamino)-1-methylbenzene and/or one of the physiologically acceptable salts thereof, and (D) as a coupler, at least one m-dihydroxybenzene derivative from the group consisting resorcinol, 2-methylresorcinol and/or 4-chlororesorcinol as coupler.

Abstract: An agent for oxidatively dyeing keratinous fibers includes in a cosmetic carrier: (A) 4,5-diamino-1-(2-hydroxyethyl)-1H-pyrazole and/or one of the physiologically acceptable salts thereof as developer; (B) at least one p-aminophenol derivative from the group comprising p-aminophenol, 4-amino-3-methylphenol, and/or the physiologically acceptable salts thereof as developer; (C) at least one m-diaminobenzene derivative from the group comprising 2-(2,4-diaminophenoxy)ethanol, 1-methoxy-2-amino-4-(2?-hydroxyethylamino)benzene, 2,6-bis(2?-hydroxyethylamino)-1-methylbenzene, and/or one of the physiologically compatible salts thereof as coupler; and (D) at least one m-aminophenol derivative from the group 3-aminophenol, 5-amino-2-methylphenol and/or one of the physiologically acceptable salts thereof as coupler, wherein the molar ratio of all the developers of group (A) included in the agent to all the developers of group (B) included in the agent, i.e., the molar ratio (A)/(B), has a value of at least 1.2.

Abstract: An agent for oxidatively dyeing of keratinic fibers includes, in a cosmetic carrier, (A) 4,5-diamino-1-(2-hydroxyethyl)-1H-pyrazole and/or one of the physiologically acceptable salts thereof as developer, (B) at least one pyrimidine derivative selected from 2,4,5,6-tetraaminopyrimidin, 4-hydroxy-2,5,6-triaminopyrimidin, 2-hydroxy-4,5,6-triaminopyrimidin and/or one of the physiologically acceptable salts thereof as developer, (C) at least one m-diaminobenzene derivative selected from 2-(2,4-diaminophenoxy)ethanol, 1-methoxy-2-amino-4-(2?-hydroxyethylamino)benzene, 2,6-bis(2?-hydroxy-ethylamino)-1-methylbenzene, and/or one of the physiologically acceptable salts thereof as coupler, and (D) at least one m-dihydroxybenzoyl derivative selected from resorcinol, 2-methylresorcinol and/or 4-chlororesorcinol as coupler.

Abstract: A composition including at least a polyol for the prevention of oral and dental infections or diseases and/or maintaining good oral and dental hygiene, thus allowing the maintenance of good oral and dental health. More specifically, treating demineralisation of dental enamel, and especially for stimulating remineralisation thereof, using the composition including at least one polyol selected from maltitol and xylitol.

Abstract: The present invention relates to targeted microcapsules or nanocapsules comprising a skin whitening compound to target melanocytes with a peptide, which is a MC1 receptor agonist, wherein said peptide is coupled to the outer surface of the microcapsule or nanocapsule. It also relates to the use of said microcapsules or nanocapsules for the cosmetic prevention and/or cosmetic treatment of cutaneous dark spots, and to the cosmetic compositions comprising said microcapsules or nanocapsules. The invention also relates to the MC1 receptor agonist peptide coupled to the microcapsule or nanocapsule. The invention also relates to a peptide for use as skin whitening compound.

Abstract: The present invention relates to a solution solubilization composition of an insoluble material and a method for solubilizing an insoluble material using the same, on the basis of the mechanism that a solution solubilization composition of an insoluble material comprising mannosylerythritol lipid, an insoluble material, a heteropolysaccharide, a surfactant and a polyol offsets the intermolecular interaction of a hydrophobic material without physical requirements.

Abstract: The present invention relates to a cosmetic formulation for the treatment of deep wrinkles of the skin and other skin disorders by means of iontophoresis, said formulation comprising the following active ingredients: dimethylaminoethanol (DMAE) with a tightening and firming effect; hyaluronic acid with a moisturizing and filling effect; and vitamin C with an antioxidant characteristic, including its ethyl ascorbic acid form, The formulation can additionally include one or more other ingredients for the treatment of other disorders, including: magnesium ascorbyl phosphate (MAP), lipoic acid, carnitine, ellagic acid, magnesium ascorbyl phosphate (MAP), vitamin K oxide, Kojic acid dipaimitate, phytic acid, copper sulfate, zinc sulfate, glycolic acid, salicylic acid and potassium azeloyl diglycinate.

Abstract: The present invention was aimed to provide a low-stringiness thickener consisting of a compound in high demand as a thickener for cosmetics, i.e., polyacrylic acid or a salt thereof, or PAMPS or a salt thereof, where a stringiness property of the compound was reduced. A low-stringiness thickener consisting of a compound selected from polyacrylic acid. a salt of polyacrylic acid, PAMPS, and a salt of PAMPS, wherein the weight-average molecular weight of the compound is 500 thousand to 8 million, and wherein the content of the compound having the molecular weight of 10 million or higher is 10 mass % or less.

Abstract: Method and kit for providing visual effects on fibres, for example human keratin fibres. In the method, fibres are provided coated with a composition. The composition comprises monomer(s) and optionally a cosmetically acceptable carrier. The monomer(s) are capable of forming a polymer after exposure to electromagnetic radiation having a wavelength of from about 300 nm to about 750 nm. The monomer(s) are selected from the group consisting of acrylates monomers, methacrylate monomers, acrylamide monomers, methacrylamide monomers, styrene monomers, vinyl pyrrolidinone monomers, vinylpyrrolidone monomers, and mixtures thereof. The monomer(s) have a molecular weight in the range from about 100 g/mol to about 5000 g/mol. The monomer(s) have a functionality of between 1 and 100. The composition has a kinematic viscosity of from about 0.5 cSt to about 1500 cSt, measured at 23° C. In the method, a forming means is applied onto the fibres.

Abstract: The invention relates to a hair treatment agent including 0.1 to 20 weight percent of at least one silicone including groups of the formula (I) as defined herein; 0.1 to 20 weight percent of at least one copolymer that includes monomer units of the formulas (V) and (VI) as defined herein; and 0.5 to 5 weight percent of 2-phenylbenzimidazole-5-sulfonic acid. The hair treatment agent according to the invention has an improved protective effect against UV radiation and has an improving effect on hair treated therewith with regard to combability, gloss, elasticity, brittleness, and maximum tensile strength.

Abstract: Uses of polymers including monomeric units based on salts of itaconic acid as film formers are disclosed. The polymers confer good film-forming characteristics to the compositions to which they are added, making them suitable for use in cosmetic and personal care product, in particular those that are applied to the skin, hair or nails. The polymers offer a variety of benefits to the products into which they are incorporated, increasing their performance, longevity or adhesion to the human body and improving their feel or appearance during use. Also disclosed are methods of preparing the polymers and the cosmetic and personal care compositions.

Abstract: The invention relates generally to pigmented compositions that, upon the application of water and pressure, exhibit a visible change in one or more optical attributes such as color.

Abstract: This invention relates to the use of cationically UV curable compositions to coat nails, cationically UV curable nail coating compositions and methods of making up nails using said compositions. In a preferred embodiment, the cationically UV curable nail coating compositions comprise at least one epoxy resin. The epoxy resin may be of plant origin.

Abstract: The disclosure provides a personal care composition and method for forming the composition wherein the SCC polymer has at least one functionality selected from the group consisting of silicone, hydroxyl and carboxy. Such functionalized SCC polymers can be employed in a wide range of personal care compositions including skin care, body wash, and shampoo and hair treatments, among other personal care products.

Abstract: Hair treatment compositions that include, based in each case on their weight, 0.1 to 20 wt % of at least one silicone having groups of the formula (I) as defined herein; 0.1 to 20 wt % of at least one copolymer which includes monomer units of the formulae (V) and (VI) as defined herein; and 0.5 to 5 wt % of 2-phenylbenzimidazole-5-sulfonic acid, possess an improved protective effect relative to UV radiation and endow the hair treated with them with enhanced combability, gloss, elasticity, brittleness and maximum tear resistance.

Abstract: The invention relates to a hair treatment agents, including—in each case with respect to the weight of the hair treatment agents—0.1 to 20 wt % of at least one silicone, which has groups of formula (I) as defined herein; 0.1 to 20 wt % of at least one copolymer, which has monomer units of formulas (V) and (VI) as defined herein; and 0.1 to 10 wt % of (RS)-2-cyano-3,3-diphenylacrylic acid-2-ethylhexylester. The hair treatment agents have an improved protective effect against UV radiation and give hair treated with said hair treatment agents better combability, shine, elasticity, brittleness, and maximum tear resistance.

Abstract: The present invention allows a plant seed that contains at least galacturonic acid and rhamnose as constituents to be reduced in a general bacterial count to a cosmetically acceptable level by placing the plant seed under reduced pressure, subsequently exposing the plant seed in bacteriocidal gas atmosphere with higher pressure than atmospheric pressure, and then placing the plant seed under reduced pressure. The plant seed of the present invention can form a pectic coat in water upon soaking in the water. The bacteriocidal in the present invention can be selected from any combination of ethylene oxide, ethylene glycol, ethylene chlorohydrin, and inert gas.

Abstract: The present invention relates to the cosmetic use of a lysate of a bacterium or bacteria belonging to the Vitreoscilla sp. genus (in particular of the Vitreoscilla filiformis species) in a complete fermentation medium, as an active agent for preventing and/or treating hyperseborrhoeic conditions not associated with a dandruff condition of the scalp.

Abstract: The present disclosure relates to the treatment of tuberculosis and/or multi-drug resistant tuberculosis by inhalable pharmaceutical compositions that include an interferon and at least one therapeutic agent selected from the group of fluoroquinolone, aminoglycoside and nitroimidazole. The present disclosure also relates to an inhalable pharmaceutical composition that includes an interferon and at least one therapeutic agent selected from the group of fluoroquinolone, aminoglycoside and nitroimidazole.

Abstract: A handheld device for mixing a liquid and a gas to form foam before a treatment procedure comprises: an inlet for letting a liquid enter the device, the inlet adapted for attachment to a syringe containing the liquid, an outlet for letting a formed foam exit the device, a chamber containing a gas, the chamber comprising the inlet and outlet, at least one agitation element disposed in the chamber, the at least one agitation element is arranged for independent movement in at least one degree of freedom, the at least one agitation element sized and shaped to mechanically agitate liquid flowing past the at least one agitation element, the liquid flowing in an overall inlet-to-outlet direction, the agitation being sufficient for the at least some of the liquid to mix with the gas to produce the formed foam; the device is dimensioned for holding in one hand.

Abstract: An object of the present invention is to provide a disintegrative particulate composition that can be used for an orally disintegrating tablet having both excellent tablet hardness and disintegrability. This invention relates to a method for the production of a disintegrative particulate composition including three components consisting of a first disintegrator component having sedimentation volume in water of 4.0 cm3/g or more, a second disintegrator component other than the first disintegrator component and an excipient, which comprises a first wet granulation step using any two of the three components and a second wet granulation step using the granules obtained in the first wet granulation step and at least the remaining one component not used in the first wet granulation step; the disintegrative particulate composition thus produced; and an orally disintegrating tablet comprising a medicinal ingredient and the disintegrative particulate composition.

Abstract: A high dose orodispersible dosage form of oxcarbazepine is provided. Drug-containing particles of oxcarbazepine are included within a porous bound matrix. The dosage form disperses in saliva or water in less than 15 sec and it has sufficient hardness to withstand handling and storage. It can be used to treat diseases or disorders that are therapeutically responsive to oxcarbazepine or a derivative thereof.

Abstract: A method for manufacturing a drug-delivery composition includes providing at least a pharmaceutically active composition, providing a hydrophobic matrix; and mixing the hydrophobic matrix and the pharmaceutically active composition to form a paste-like or semi-solid drug-delivery composition.

Abstract: A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.

Abstract: A single dosage form that delivers a tripulse (i.e., three pulses) release profile is provided. The dosage form includes at least three dosage units inside the final dosage form. By providing a single dosage form with multiple dosage units, the dosing frequency is decreased since precise blood levels of the active over a prolonged time period are controlled and achieved.

Abstract: The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine.

Abstract: Highly compactable granulations and methods for preparing highly compactable granulations are disclosed. More particularly, highly compactable calcium carbonate granulations are disclosed. The granulations comprise powdered materials such as calcium carbonate that have small median particle sizes. The disclosed granulations are useful in pharmaceutical and nutraceutical tableting and provide smaller tablet sizes upon compression than previously available.

Abstract: This invention relates to prophylactic and/or therapeutic application of microorganism species that are, for example, administered orally as delayed release formulation designed to release its microbial content to the distal small intestine and/or colon in high quantities and density, which is a “normalized” approach to repopulate the colonic flora as a method of prevention and/or treatment of, for example, Clostridium difficile colitis.

Abstract: Provided herein are methods of inhibiting proliferation of one or more tumor cells comprising contacting the one or more tumor cells with a composition comprising one or more epigenetic drugs that inhibit one or more epigenetic mechanisms of the tumor cells, wherein the one or more epigenetic drugs are encapsulated in a nanogel. The invention is also directed to methods of treating a tumor, metastasis of a tumor or a combination thereof in an individual in need thereof. The invention is also directed to a method of sequentially delivering one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell and one or more chemotherapeutic drugs to an individual that has a tumor. Compositions which comprise one or more epigenetic drugs that alter one or more epigenetic mechanisms of a tumor cell, wherein the one or more epigenetic drugs are encapsulated in a nanogel.

Abstract: The present invention relates to the field of methods for providing components of pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to methods for providing stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions.

Abstract: The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including testosterone esters, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided.

Abstract: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film. The films contain a polymer component, which includes polyethylene oxide optionally blended with hydrophilic cellulosic polymers. Desirably, the films also contain a pharmaceutical and/or cosmetic active agent with no more than a 10% variance of the active agent pharmaceutical and/or cosmetic active agent per unit area of the film. The invention further relates to edible multi-layer films that dissolve in water. In particular, the edible multi-layer films have a first water-soluble film layer and one or more additional water-soluble film layers in at least partial face-to-face engagement with the first film layer.

Abstract: The present invention provides transdermal absorption preparation having a support, and a drug-containing adhesive layer formed on the support, wherein a drug-containing adhesive layer contains donepezil or a salt thereof, and a higher fatty acid salt.

Abstract: Methods and formulations for infusing bioavailable flavonoid tinctures into food, beverage, cosmetic or drug products with minimal or no effect on the alcohol by volume of the product is provided. A flavonoid tincture includes an amount of trans-resveratrol, pterostilbene, quercetin, or combinations thereof, mixed with a solvent of pure, or majority by weight, ethanol or Dimethyl sulfoxide The tincture is added to various food and beverages to make a bioavailable amount of flavonoids to be absorbed and metabolized by the body providing demonstrated health benefits.

Abstract: The instant invention provides methods and compositions for the treatment and prevention of cell proliferative disorders.

Abstract: A composition that includes at least two of: echinochrome A (2-ethyl-3,5,6,7,8-pentahydroxy-1,4-naphthoquinone); spinochrome A (2-acetyl-3,5,6,8-tetrahydroxy-1,4-naphthalenedione); spinochrome B (2,3,5,7-tetrahydroxy-1,4-naphthalenedione); spinochrome C (2-acetyl-3,5,6,7,8-pentahydroxy-1,4-naphthalenedione); spinochrome D (2,3,5,6,8-Pentahydroxy-1,4-naphthalenedione); and spinochrome E (hexahydroxy-1,4-naphthalenedione). The composition can include one or more additional active ingredients (e.g., vitamin, tretinoin (alltrans retinoic acid or ATRA), a glycosaminoglycan (GAG), dermal filler, Botulinum toxin, etc.) and/or one or more inactive ingredients (e.g., solvent, carrier, gelling agent, coloring agent, etc.). The composition can be in a dry, solid form (e.g., powder), or in a liquid form. Additionally, each of the above components above can independently be present in the composition in either the naturally derived form, or in a synthetically prepared form.

Abstract: Vitamin K is effective in counteracting cardiovascular disorders such as the reduction in arterial elasticity normally associated with the aging process. A pharmaceutical composition or nutritional formulation comprising vitamin K can be used to combat age-related stiffening of the arteries, and the consequences thereof, namely pulmonary congestion, hypertension, left ventricular hypertrophy, congestive (right sided) heart failure, left sided or left ventricular failure, chronic cardiac failure, angina pectoris, myocardial infarction, Mönckeberg's sclerosis and stroke. In various embodiments, vitamin K can also be used to reduce or reverse calcification of a blood vessel in pre-existing cardiovascular disorders such as arteriosclerosis.

Abstract: The invention provides methods for treating CNS-related conditions with amantadine and donepezil, in which the amantadine is in an extended release form, wherein the extended release amantadine formulation provides a change in plasma concentration as a function of time (dC/dT) that is less than 40% of the dC/dT of the same quantity of an immediate release form of amantadine.

Abstract: Embodiments of the present disclosure are generally related to a method and apparatus of delivering medication to treat the symptoms of anaphylactic shock. In particular, certain embodiments deliver dosages epinephrine and Benadryl intramuscularly using an auto-injection device. In certain embodiments, the dosages of epinephrine and Benadryl are delivered in a dosage and timing to increase the efficacy in treating the symptoms of anaphylactic shock.

Abstract: The present findings point to mutant HSCs as the cause of BM neuroglial damage that compromises MSC survival and function, critically contributing to MPN pathogenesis. In this sense, the present invention shows that the niche damage triggered by the mutant HSC is essential for the development of a haematopoietic malignancy previously considered to be caused by the HSC alone. Targeting HSC niche-forming MSCs and their neural regulation paves the way to more efficient therapeutic strategies in MPN. For this purpose, the present invention shows that an efficient therapeutic strategy for the treatment of MPN lies on the administration of neuroprotective compounds, such as 4-methylcatechol, capable of protecting BM sympathetic nerve fibres. Additionally, another efficient therapeutic strategy is shown herein as the administration of selective ?3-adrenergic agonists such as BRL37344 or Mirabegron, since this strategy will compensate for deficient sympathetic stimulation of nestin+ MSCs.

Abstract: The present invention relates to a novel use and methods of treatment using sympathicomimetic agonists with pro-hemostatic activity.

Abstract: The present invention relates, in general, to agents that modulate the pharmacological activity of nucleic acid molecules and, in particular, to agents that bind therapeutic or diagnostic nucleic acid molecules in a sequence independent manner and modulate (e.g., inhibit or reverse) their activity. The invention also relates to compositions comprising such agents and to methods of using same.

Abstract: Disclosed herein is a method for the treatment of an infection with, or disease caused by, Chikungunya virus in a subject. The method includes administering to the subject a therapeutically effective amount of suramin as the active agent.

Abstract: The present invention includes novel chemical formulations having antimicrobial activity and their methods of use thereof. In some embodiments, the formulation further comprises at least one fungus.

Abstract: The present invention relates to short chain fatty acids (SCFA) for use in transmucosal administration to a subject for the prevention, attenuation or treatment of a disease or disorder associated with a compromised Th1 immune response and/or an unwanted Th2 or Th2-like immune response by modulating a Th2 immune response towards a Th1 immune response, particularly for the treatment, prevention and/or amelioration of viral infections and as an adjuvant for promoting the efficiency of vaccines and/or prevention of allergic diseases or disorders.